HomeCompareSPRT vs PFE

SPRT vs PFE: Dividend Comparison 2026

SPRT yields 8.47% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $14.5K in total portfolio value· pulled ahead in Year 10
10 years
SPRT
SPRT
● Live price
8.47%
Share price
$11.80
Annual div
$1.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$35.0K
Annual income
$1,447.58
Full SPRT calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — SPRT vs PFE

📍 PFE pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSPRTPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SPRT + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SPRT pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SPRT
Annual income on $10K today (after 15% tax)
$720.34/yr
After 10yr DRIP, annual income (after tax)
$1,230.44/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $21,089.46/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SPRT + PFE for your $10,000?

SPRT: 50%PFE: 50%
100% PFE50/50100% SPRT
Portfolio after 10yr
$42.3K
Annual income
$13,853.15/yr
Blended yield
32.75%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

SPRT
Analyst Ratings
1
Buy
2
Hold
Consensus: Hold
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SPRT buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSPRTPFE
Forward yield8.47%6.13%
Annual dividend / share$1.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$35.0K$49.6K
Annual income after 10y$1,447.58$26,258.71
Total dividends collected$11.5K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldHold

Year-by-year: SPRT vs PFE ($10,000, DRIP)

YearSPRT PortfolioSPRT Income/yrPFE PortfolioPFE Income/yrGap
1$11,547$847.46$9,153$693.39+$2.4KSPRT
2$13,270$914.58$8,593$849.25+$4.7KSPRT
3$15,182$982.27$8,336$1,066.78+$6.8KSPRT
4$17,294$1,050.23$8,437$1,384.80+$8.9KSPRT
5$19,623$1,118.13$9,013$1,875.40+$10.6KSPRT
6$22,183$1,185.69$10,306$2,680.72+$11.9KSPRT
7$24,988$1,252.64$12,820$4,101.38+$12.2KSPRT
8$28,056$1,318.75$17,673$6,826.70+$10.4KSPRT
9$31,404$1,383.79$27,543$12,591.86+$3.9KSPRT
10← crossover$35,049$1,447.58$49,560$26,258.71$14.5KPFE

SPRT vs PFE: Complete Analysis 2026

SPRTStock

Support.com, Inc. provides customer support services, end user software, and cloud-based software primarily in the United States. The company offers turnkey and outsourced support services for service providers, retailers, original equipment manufacturers (OEMs), warranty providers, Internet of Things solution providers, and other technology companies. Its customer support services programs include pre-purchased concierge advice, device set-up and troubleshooting, inter-operability problem resolution, and virus and malware removal, wireless network set-up, and home security and automation system onboarding and support designed for consumer, and small and medium business markets. The company also provides Support.com Cloud, a software-as-a-service solution for companies to optimize support interactions with their customers using their own or third party support personnel, as well as enables companies to resolve complex technology issues for their customers, provide ease of use for customer self-service, and enhance the customer experience. In addition, it offers end-user software products, including SUPERAntiSpyware for malware protection and removal. The company provides its technology support services through partners. Support.com, Inc. was founded in 1997 and is headquartered in Wilmington, Delaware.

Full SPRT Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this SPRT vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SPRT vs SCHDSPRT vs JEPISPRT vs OSPRT vs KOSPRT vs MAINSPRT vs JNJSPRT vs MRKSPRT vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.